Steve Brozak's Stock Ratings

WBB Securities Analyst

Steve Brozak is an analyst at WBB Securities. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 06/25/2025

Overall Average Return

-22.1%

Smart Score

25.4%

Overall Average Return Percentile

10th

Number of Ratings

15
Buy NowGet Alert
06/23/2025CDTXBuy Now
Cidara Therapeutics
$43.403.69%
Steve Brozak25%
$45 → $45ReiteratesStrong Buy → Strong BuyGet Alert
04/01/2025MRKRBuy Now
Marker Therapeutics
$1.47750.34%
Steve Brozak25%
$12.5 → $12.5ReiteratesStrong Buy → Strong BuyGet Alert
06/08/2022CFRXBuy Now
ContraFect
Steve Brozak25%
→ $7UpgradeBuy → Strong BuyGet Alert
02/10/2022PRTKBuy Now
Paratek Pharmaceuticals
Steve Brozak25%
→ $11UpgradeBuy → Strong BuyGet Alert
02/02/2022CFRXBuy Now
ContraFect
Steve Brozak25%
→ $6.5UpgradeSpeculative Buy → BuyGet Alert
09/22/2021CDTXBuy Now
Cidara Therapeutics
$43.40
Steve Brozak25%
UpgradeBuy → Strong BuyGet Alert
08/11/2021CWBRBuy Now
CohBar
$0.411119.51%
Steve Brozak25%
→ $5UpgradeSpeculative Buy → BuyGet Alert
06/18/2021OMERBuy Now
Omeros
$3.322912.05%
Steve Brozak25%
$75 → $100MaintainsStrong BuyGet Alert
05/28/2021RDHLBuy Now
Redhill Biopharma
$1.89746.56%
Steve Brozak25%
$17 → $16DowngradeStrong Buy → BuyGet Alert
04/23/2021PRTKBuy Now
Paratek Pharmaceuticals
Steve Brozak25%
→ $10UpgradeSpeculative Buy → BuyGet Alert
03/31/2021CFRXBuy Now
ContraFect
Steve Brozak25%
→ $6.5Initiates → Speculative BuyGet Alert
10/15/2020CWBRBuy Now
CohBar
$0.41997.56%
Steve Brozak25%
→ $4.5Initiates → Speculative BuyGet Alert
07/12/2019RDHLBuy Now
Redhill Biopharma
$1.89799.47%
Steve Brozak25%
→ $17UpgradeBuy → Strong BuyGet Alert
03/12/2019RDHLBuy Now
Redhill Biopharma
$1.89799.47%
Steve Brozak25%
→ $17UpgradeSpeculative Buy → BuyGet Alert
04/18/2013OMERBuy Now
Omeros
$3.32502.41%
Steve Brozak25%
→ $20MaintainsStrong BuyGet Alert